Menu
Back to User profile » Dr Arshad M Khanani
Papers published by Dr Arshad M Khanani:
Impact of Modifying Abicipar Manufacturing Process in Patients with Neovascular Age-Related Macular Degeneration: MAPLE Study Results
Callanan D, Khurana RN, Maturi RK, Patel S, Wykoff CC, Eichenbaum D, Khanani AM, Hassan T, Badger H, Mehta S, Le G, Attar M, Seal J, Li XY
Clinical Ophthalmology 2023, 17:1367-1384
Published Date: 11 May 2023
Emerging Treatment Options for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
Khan H, Aziz AA, Sulahria H, Khan H, Ahmed A, Choudhry N, Narayanan R, Danzig C, Khanani AM
Clinical Ophthalmology 2023, 17:321-327
Published Date: 23 January 2023
Cooling Anesthesia for Intravitreal Injections – A Review
Chandrasekaran PR, Aziz AA, Khan H, Khanani AM
Clinical Ophthalmology 2023, 17:197-207
Published Date: 13 January 2023
Macular Telangiectasia Type 2: A Comprehensive Review
Kedarisetti KC, Narayanan R, Stewart MW, Reddy Gurram N, Khanani AM
Clinical Ophthalmology 2022, 16:3297-3309
Published Date: 10 October 2022
Cooling Anesthesia for Intravitreal Injection: Results of the Prospective Open-Label, Dose-Ranging COOL-1 Trial
Chao DL, Rinella NT, Khanani AM, Wykoff CC, Kim GH
Clinical Ophthalmology 2021, 15:4659-4666
Published Date: 10 December 2021
Angiopoietins as Potential Targets in Management of Retinal Disease
Khanani AM, Russell MW, Aziz AA, Danzig CJ, Weng CY, Eichenbaum DA, Singh RP
Clinical Ophthalmology 2021, 15:3747-3755
Published Date: 4 September 2021
Retrospective Study of Ellipsoid Zone Integrity Following Treatment with Intravitreal Ocriplasmin (OZONE Study)
Drenser KA, Pieramici DJ, Gunn JM, Rosberger DF, Kozma P, Fineman MS, Duchateau L, Khanani AM
Clinical Ophthalmology 2021, 15:3109-3120
Published Date: 16 July 2021
Predictors of Early Diabetic Retinopathy Regression with Ranibizumab in the RIDE and RISE Clinical Trials
Singer M, Liu M, Schlottmann PG, Khanani AM, Hemphill M, Hill L, Tuomi L, Haskova Z
Clinical Ophthalmology 2020, 14:1629-1639
Published Date: 17 June 2020
Five-year outcomes of intravitreal drug therapy for neovascular age-related macular degeneration in eyes with baseline vision 20/60 or better
Khanani AM, Gahn GM, Koci MM, Dang JM, Brown SM, Hill LF
Clinical Ophthalmology 2019, 13:347-351
Published Date: 13 February 2019
Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections: a USA claims analysis
Kiss S, Dugel PU, Khanani AM, Broder MS, Chang E, Sun GH, Turpcu A
Clinical Ophthalmology 2018, 12:1625-1635
Published Date: 30 August 2018
Clinical experience with fixed bimonthly aflibercept dosing in treatment-experienced patients with neovascular age-related macular degeneration
Khanani AM
Clinical Ophthalmology 2015, 9:1315-1320
Published Date: 22 July 2015